ACTO Recognized as a Luminary in Everest Group's Agentic AI Innovation Watch for Life Sciences 2026

ACTO's Innovative Approach Recognized

On October 5, 2026, ACTO, a pioneer in integrating human intelligence with AI, proudly announced its recognition as a Luminary in the Everest Group's recent report, "Innovation Watch: Agentic AI in Life Sciences Commercial 2026". This accolade highlights ACTO's cutting-edge role-based SuperAgents and its unique focus on the life sciences sector, positioning the company as a leader within this rapidly evolving field.

Understanding the Everest Group Assessment

The Everest Group's comprehensive report evaluates 22 AI technology providers based on two critical dimensions: market performance, which assesses the scale and maturity of each provider, and ecosystem drivers, which look into partnerships and investments. The companies are classified into four categories: Luminaries, Fast Followers, Influencers, or Seekers. ACTO's designation as a Luminary reflects its exceptional market performance and robust ecosystem presence.

This recognition comes at a pivotal time as agentic AI is revolutionizing commercial operations in life sciences. The Everest report underlines the potential of this technology across various functions such as sales, marketing, medical affairs, market access, and patient services. Organizations are increasingly leveraging agentic AI to enhance decision-making, streamline operations, and create personalized engagement experiences.

According to Rohit K, Practice Director at Everest Group, "As companies in the life sciences sector adopt agentic AI, the paradigm is shifting from isolated AI applications to interconnected commercial platforms that unify data, content, and workflows across roles and systems. The effectiveness of agentic AI will hinge on its capability to synchronize activities across different functions while maintaining oversight, traceability, and human accountability."

ACTO's Unique Offering

ACTO's approach to agentic AI distinguishes itself through the deployment of SuperAgents designed specifically for the life sciences industry. These intelligent agents facilitate seamless orchestration of tasks, ensuring compliance and timely support for customer-facing professionals. From retrieving clinical and scientific information to providing on-the-job training and tracking field insights, ACTO's AI solutions empower teams to prioritize meaningful interactions with healthcare professionals.

"We are honored to be acknowledged as a Luminary by Everest Group, joining our respected partners Veeva and Salesforce in this achievement," stated Parth Khanna, Co-founder and CEO of ACTO. "Our commitment to agentic AI began in 2022, driven by the belief that AI could transform work dynamics in life sciences—not by replacing human talent but by augmenting it. This vision has now become a reality. Our clients recognize immense value in our role-based SuperAgents that comprehend individual responsibilities, the nature of their work, and the strict regulatory landscape that characterizes the industry."

Built for life sciences, ACTO combines its AI-powered Field Excellence Platform with these SuperAgents to enhance operational effectiveness while meeting the highest regulatory standards. Notably, ACTO is FDA 21 CFR Part 11 validated and SOC 2 Type II certified, ensuring that its offerings adhere to the industry’s rigorous compliance requirements.

Earlier in 2026, ACTO was also featured among the Everest Group's Top 50™ Pharmaceutical Technology Providers, further cementing its dedication to advancements in AI-powered field excellence and its focus on agentic AI tailored for life sciences.

For those interested in learning more about ACTO's role-based SuperAgents, a free copy of the comprehensive report is available for download. Visit acto.com/superagents for additional insights.

About ACTO and Everest Group

ACTO is trusted by 14 of the top 50 pharmaceutical companies, promising to reshape how therapies are delivered post-regulatory approval. By integrating human insight with empathetic AI, ACTO's technology aims to speed up product launches and enhance customer engagement, helping teams focus on fostering meaningful connections.

Everest Group, recognized for its authoritative research, aids business leaders in making informed decisions. Their PEAK Matrix® assessments provide vital insights and analysis, enabling enterprises to evaluate service providers effectively.

For more updates, readers can follow ACTO on LinkedIn or visit their website at acto.com.